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Abstract
Background: FibroTest and elastography have been validated as biomarkers of liver fibrosis in the most frequent 
chronic liver diseases and in the fibrosis screening of patients with diabetes. One challenge was to use them for 
estimating the prevalence of fibrosis, identifying independent risk factors and to propose screening strategies in the 
general population.
Methods: We prospectively studied 7,463 consecutive subjects aged 40 years or older. Subjects with presumed 
advanced fibrosis (FibroTest greater than 0.48) were re-investigated in a tertiary center.
Results: The sample characteristics were similar to those of the French population. FibroTest was interpretable in 
99.6%. The prevalence of presumed fibrosis was 2.8%, (209/7,463), including cirrhosis in 0.3% (25/7,463); 105/209 (50%) 
subjects with presumed fibrosis accepted re-investigation. Fibrosis was confirmed in 50, still suspected in 27, 
indeterminate in 25 and not confirmed with false positive FibroTest or false negative elastography in 3 subjects. False 
negative rate of FibroTest estimated using elastography was 0.4% (3/766). The attributable causes for confirmed fibrosis 
were both alcoholic and nonalcoholic fatty liver disease (NAFLD) in 66%, NAFLD in 13%, alcohol in 9%, HCV in 6%, and 
other in 6%. Factors independently associated (all P < 0.003) with confirmed fibrosis were age, male gender, waist 
circumference, HCV antibody and alcohol consumption estimated using carbohydrate-deficient transferrin, enabling 
efficient screening-oriented strategies to be compared and proposed.
Conclusions: Biomarkers have permitted to estimate prevalence of advanced fibrosis around 2.8% in a general 
population aged 40 years or older, and several risk factors which may be used for the validation of selective or non-
selective screening strategies.
Background
Screening for liver fibrosis is increasingly appropriate as
three major recommended criteria have now been ful-
filled, including the disease severity, the tests accuracy
and the effectiveness of treatments [1].
First, liver fibrosis is a significant health problem with a
worldwide mortality attributable to cirrhosis and primary
liver cancer of around 1.5 millions death per year, with in
France (1/100 of world population) a similar mortality
rate around 15,000 death per year [2]. Cirrhosis is the last
stage of fibrosis which occurs mainly in response to viral
and toxic-metabolic insults. The most common causes of
fibrosis progression are chronic hepatitis C, chronic hep-
atitis B, alcoholic liver disease and nonalcoholic fatty liver
disease [3].
Second, liver fibrosis is detectable with non-invasive
markers [4-6]. They are many fibrosis biomarkers and the
two most investigated and validated biomarkers are the
FibroTest (FT), a serum in vitro multivariate assay
(FibroTest®, Biopredictive, Paris, France; FibroSURE® in
the USA, LabCorp, Burlington), and the Fibroscan [Echo-
sens, Paris, France], a measure of liver stiffness (LSM)
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using elastography [4-9]. FT and LSM have similar accu-
racy for the diagnosis of cirrhosis, with FT having higher
sensitivity for the diagnosis of earlier stages of fibro-
sis[10]. FT has already been evaluated in two screening
studies in high-risk populations: a retrospective study in
hyperlipidemic subjects and a prospective study in dia-
betic subjects. These results were concordant with a
prevalence of presumed advanced (bridging) fibrosis of
6% in subjects with type 2 diabetes [11,12].
Third, liver fibrosis is treatable, even at the cirrhotic
stage, mainly using anti-viral treatments for hepatitis C
and B, but also by reducing alcohol consumption and
improving overweight, diabetes and metabolic factors for
nonalcoholic fatty liver disease [13]. Whatever the cause
of cirrhosis, prevention of variceal bleeding and detection
o f  s m a l l  l i v e r  c a n c e r  i n  p a t i e n t s  w i t h  c i r r h o s i s  c a n
improve survival [12,14].
The aim of the present pilot study was to assess the fea-
sibility of the first steps of fibrosis screening using bio-
markers. Screening is a chain of activities that starts with
defining the target population and extends to the treat-
ment and follow-up of the screen-detected patients.1 The
aim was not to re-assess biomarkers' accuracy using
biopsy as this mandatory step has been extensively vali-
dated in the most frequent chronic liver diseases includ-
ing methods without perfect gold standards [10].
The primary aim was to use FT, as a first-line sensitive
test and elastography as a confirmation test to estimate
the prevalence of advanced fibrosis in a general popula-
tion. The secondary aim was to identify independent risk
factors of fibrosis and to compare the accuracy of a non
selective screening versus selective screenings.
Methods
Inclusion criteria
Consecutive subjects, forty years of age or older, who
were seen for a free screening program in two French
Social Security health examination centers were eligible
for inclusion. All procedures were performed in accor-
dance with the current revised guidelines of the Declara-
tion of Helsinki, approved by the ethical committee of
Groupe Hospitalier Pitié Salpêtrière and all investigated
participants gave informed signed consent. Forty years
threshold was chosen as fibrosis progression is very slow
in younger patients [3].
Initial medical screening
Screened subjects filled out a questionnaire, underwent
an interview and physical examination by a physician,
and blood sampling. The questionnaire included 70 epi-
demiological, clinical and environmental characteristics.
The blood sample included liver function tests, fasting
glucose, lipids, and biomarkers of fibrosis (FT), steatosis
(SteatoTest), and NASH (NashTest) [5,6] (Table 1). In a
consecutive subpopulation the serum carbohydrate-defi-
cient transferrin (CDT) was measured in order to
improve the identification of subjects with excessive
drinking [15].
The previous standard of care in these prevention cen-
ters remained unchanged. There was already a "viral hep-
atitis C or B"-oriented strategy. When the physician of the
prevention center suspected a risk of HCV or HBV infec-
tion or if the transaminase ALT level was above normal,
an HCV antibody or HBsAg antigen assay was routinely
performed and the patient was re-investigated if they
were positive.
Reinvestigation
Advanced fibrosis was "presumed" when FT was greater
than 0.48. This threshold was validated for METAVIR
scoring system advanced fibrosis (few septa, many septa,
cirrhosis) in HCV, HBV and equivalent bridging fibrosis
in ALD and NAFLD [3]. Subjects with presumed fibrosis
were contacted for a reinvestigation in the reference cen-
ter. Reinvestigation consisted of a hepatologist consulta-
tion, a second FT, an elastography (LSM), serum markers
of chronic liver disease, and if necessary, liver ultrasonog-
raphy, esophageal endoscopy, or liver biopsy.
Analysis Design
The primary analysis estimated the prevalence of fibrosis
and its associated risk factors and was performed in all
included subjects without any previous history of liver
disease.
The secondary analysis compared the non selective
screening to three risk-oriented strategies. The HCV/
HBV-oriented risk population was the previous standard
of care. The alcohol-oriented risk population included all
subjects who drank more than 10 grams a day for females
and more than 20 grams for males [16]. The metabolic
syndrome-oriented population included all subjects with
at least one factor of the metabolic syndrome (Table 1).
A third analysis was planned to assess the number of
possible false negative cases missed using FT alone. In a
consecutive population, FT and LSM were performed on
the same day in the prevention center by the same opera-
tors of the reference center.
Sample size
For the primary analysis it had been estimated that at
least 7,500 subjects would be needed in order to reinves-
tigate at least 100 subjects in the reference center, assum-
ing a prevalence of 3% and an acceptance rate of 50%.
Biomarkers measurements
FT includes α2-macroglobulin, apolipoprotein A1, hapto-
globin, total bilirubin, and γ-glutamyl-transpeptidase
(GGT), adjusted for age and gender. FT scores range from
zero to 1.00. The FT, SteatoTest, NashTest componentsPoynard et al. BMC Gastroenterology 2010, 10:40
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Table 1: Characteristics of naive subjects with and without presumed advanced fibrosis
Characteristics Subjects with presumed 
fibrosis1 reinvestigated
Subjects with presumed 
fibrosis1 not reinvestigated
Subjects without presumed 
fibrosis
Number of subjects 105 104 7254
Age at serum, years 
(mean;95%CI)
66.5 (64.7-68.2) 63.6 (62.0-65.2) 56.7 (56.5-56.9)
Male (%; 95%CI) 94 (0.90;0.82-0.95) 95 (0.91;0.84-0.96) 3924 (0.54;0.53-0.55)
Tobacco consumption 63/105 (0.60;0.50-0.69) 54/104 (0.52;0.42-0.62) 3245/7247 (0.45;0.44-0.46)
No physical exercise 65/105 (0.62;0.52-0.71) 60/104 (0.58;0.48-0.67) 4685/7247 (0.65;0.64-0.66)
Retired 70 (0.67;0.57-0.76) 58 (0.56;0.46-0.66) 2224 (0.31;0.30-0.32)
Fatty liver risk factor (Alcohol 
or metabolic)
98 (0.93;0.87-0.97) 86 (0.83;0.74-0.89) 4698 (0.65;0.64-0.66)
Mean daily self-reported alcohol 
consumption
11.6 (8.2-15.0) 15.3 (11.4-19.3) 9.9 (9.6-10.3)
Self-reported alcohol 
consumption at risk2
24/105 (0.23;0.15-0.32) 28/104 (0.27;0.19-0.37) 1634/7247 (0.23;0.22-0.24)
CDT assessed 72/105 (0.69;0.59-0.77) 2/104 (0.02;0.00-0.07) 1023/7254 (0.14;0.13-0.15)
Carbohydrate Deficient 
Transferin
1.92 (1.76-2.07) 1.49 (1.24-1.74) 1.51 (1.48-1.54)
Elevated Carbohydrate Deficient 
Transferin (>1.6%)3
45/72 (0.63;0.50-0.74) NP 303/1023 (0.30;0.27-0.33)
Alcohol at risk (either reported 
consumption or CDT)3
54/72 (0.75;0.63-0.85) NP 426/1023 (42%)
BMI >= 27.0 57 (0.54;0.44-0.64) 49 (0.47;0.37-0.57) 2319/7245 (0.32;0.31-0.33)
Metabolic factor of ATP-III 
classification (at least one)
83 (0.79;0.70-0.86) 80 (0.77;0.68-0.85) 3827 (0.53;0.52-0.54)
Glucose >= 6.1 mmol/L or 
diabetes treatment
34/103 (0.33;0.24-0.43) 42/104 (0.40;0.31-0.51) 1069/7253 (0.15;0.14-0.16)
Central obesity waist >102 male 
>88 female
30/105 (0.29;0.20-0.38) 28/104 (0.27;0.19-0.37) 1162/7245 (0.16;0.15-0.17)
Triglycerides >= 1.7 mmol/L or 
fibrate treatment
43/101 (0.41;0.32-0.51) 37/104 (0.36;0.26-0.46) 1707/7199 (0.24;0.23-0.25)
Hypertension or treatment 44/105 (0.42;0.32-0.52) 41/104 (0.39;0.30-0.50) 1885/7240 (0.26;0.25-0.27)
HDL-cholesterol <1.03 mmol/L 
male <1.29 mmol/L female 
missing 2564
16/72 (0.22;0.13-0.34) 12/68 (0.18; 0.10-0.29) 328/4764 (0.07;0.06-0.08)
Steatosis predicted by 
SteatoTest
No 23/101 (0.23;0.15-0.32) 31/104 (0.30;0.21-0.40) 4174/7190 (0.58;0.57-0.59)
Minimal (1-5%) 37/101 (0.37;0.27-0.47) 33/104 (0.32;0.23-0.42) 1617/7190 (0.23;0.22-0.24)
Moderate (6-33) 19/101 (0.19;0.12-0.28) 15/104 (0.14;0.08-0.23) 706/7190 (0.10;0.09-0.11)
Marked-Severe (34-100%) 22/101 (0.22;0.14-0.31) 25/104 (0.24;0.16-0.33) 693/7190 (0.10;0.09-0.10)
Steatohepatitis predicted by 
NASHTest
7/101 (0.07;0.03-0.13) 11/104 (0.11;0.05-0.18) 62/7190 (0.009;0.007-0.011)
Risk HCV (Transfusion, tattoo, 
piercing, heroin, cocaine)
1 (0.010;0.000-0.052) 1 (0.010;0.000-0.052) 163 (0.023;0.019-0.026)
HCV antibody assessed 105/105 (1.00;0.97-1.00) 52/104 (0.50;0.40-0.60) 3473/7254 (0.48;0.47;0.49)
HCV antibody positive 5/105 (0.05;0.02-0.11) 1/52 (0.02;0.00-0.10) 26/3473 (0.008;0.005-0.011)
HIV antibody positive 1/63 (0.02;0.00-0.09) 0/6 (0.00;0.00-0.46) 1/944 (0.001;0.000-0.006)Poynard et al. BMC Gastroenterology 2010, 10:40
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were analyzed according to published recommendations
[5,6].
LSM is expressed in kilopascals (kPa). The technique
was performed by experienced hepatologists who were
blinded, and was done according to the manufacturer's
recommendations [10,17,18]. The predefined threshold
for advanced fibrosis was 7.1 kPa, 12.5 kPa for cirrhosis
and 5 kPa for minimal fibrosis [10,17-19].
Endpoints
All cutoffs were defined a priori. Advanced fibrosis was
"confirmed" if FT was greater than 0.48 and elastography
was 7.1 kPa or above; or there were endoscopic signs of
portal hypertension; or advanced fibrosis was demon-
strated on liver biopsy. Advanced fibrosis was "still sus-
pected" if FT was greater than 0.48 and LSM was between
5.0 kPa and 7.1 kPa as LSM has a lower sensitivity than
FT.10 Fibrosis was "indeterminate with suspected false
positive FT or false negative LSM" if FT was greater than
0.48 and the LSM was lower than 5.0 kPa.
The efficacy of the risk-oriented strategies was com-
pared using the number of identified advanced fibrosis
cases, the relative risk of advanced fibrosis as estimated
by the odds ratio, the AUROC for quantitative factors and
the number of persons required to undergo fibrosis
screening in order to detect one case of advanced fibrosis.
In the subpopulation with CDT measurement, the goal
was to assess whether CDT was a better predictive factor
than self-reported alcohol consumption for the predic-
tion of advanced fibrosis and for attributing the cause of
liver disease.
In the subpopulation that was also screened with LSM,
the goal was to estimate the percentage of FT false nega-
tives. Subjects with LSM 7.1 kPa or greater were system-
atically contacted for reinvestigation.
Statistical analysis
The Fisher's exact, Mann-Whitney, Bonferroni, and
Tukey-Kramer tests and logistic regression were used.
For diagnostic values, relative risk was estimated using
the odds ratio. The area under the ROC curve (AUROC)
was assessed for quantitative factors. The representative-
ness of the present general population sample enrolled in
the French Social Security health examination center
sample was assessed using comparisons with characteris-
tics of the overall French population and from a French
national survey on nutrition and health [20,21].
HBsAg assessed 105/105 (1.00;0.97-1.00) 8/104 (0.08;0.03-015) 604/7254 (0.08;0.077-0.090)
HBsAg antigen positive 2/105 (0.02;0.00-0.07) 0/104 (0.00;0.00-0.04) 5/604 (0.008; 0.003-0.019)
Liver stiffness measurement 
assessed
93/105 (0.86;0.81-0.94) 0/104 (0.00;0.00-0.04) 865/7254 (0.12;0.11-0.13)
LSM kPa 10.1 (8.3-12.0) NP 5.0 (4.8-5.1)
Markers (normal range)
AST IU/L (17-27 female; 20-32 
male)
34 (31-37) 40 (34-46) 24 (24-24)
ALT IU/L (11-26 female; 16-35 
male)
43 (37-50) 46 (38-54) 27 (26-27)
Total bilirubin mol/L (1-21) 16 (14-17) 16 (14-17) 12 (12-12)
GGT U/L (7-32 female; 11-49 
male)
72 (56-87) 111 (75-146) 27 (26-27)
Alpha 2 macroglobulin g/L 
(female 1·6-4·0; male 1·4-3·3)
2.4 (2.3-2.5) 2.4 (2.3-2.5) 1.5 (1.5-1.5)
Apo A1 g/L (1·2-1·7) 1.5 (1.4-1.5) 1.5 (1.4-1.5) 1.7 (1.7-1.7)
Haptoglobin g/L (0·35-2·00) 0.9 (0.8-1.0) 0.8 (0.7-0.9) 1.2 (1.1-1.2)
Fasting Glucose (mmol/L) 6.1 (5.8-6.4) 6.4 (6.0-6.8) 5.5 (5.5-5.5)
Cholesterol (mmol/L) 5.3 (5.1-5.5) 5.4 (5.1-5.6) 5.8 (5.7-5.8)
Triglycerides (mmol/L) 1.7 (1.3-2.0) 1.8 (1.4-2.2) 1.3 (1.3-1.3)
HDL-cholesterol (data in 72/68/
4764 subjects)
0.49 (0.46-0.51) 0.51 (0.47-0.54) 0.63 (0.62-0.63)
1 FibroTest greater than 0.48
2 More than one drink per day for females and more than two drinks per day for males
Data are mean (SD) or proportion.
3 Carbohydrate Deficient Transferin was consecutively assessed in 1038 subjects at baseline and in 59 subjects during reinvestigations.
Table 1: Characteristics of naive subjects with and without presumed advanced fibrosis (Continued)Poynard et al. BMC Gastroenterology 2010, 10:40
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Number Cruncher Statistical Systems 2007 software
(NCSS, Kaysville, Utah, USA) was used [22].
Results
Screened population
Between June 2006 and September 2008, 7,554 subjects
were eligible; 72 were excluded, including 33 because of
high-risk profiles of FT false positives or false negatives
(applicability 99.6%; 7521/7554), and 16 protocol refusal
(acceptance 99.8%; 7505/7521). Majority of high-risk pro-
files (24/33) were abnormally low haptoglobin (hemolysis
or anhaptoglobinemia), 4 subjects had abnormally high
apoA1 value, 1 abnormally low ApoA1, 2 abnormally high
GGT, one Gilbert syndrome with 72 micromol of uncon-
jugated bilirubin, and one abnormally high A2 M.
Among the 7,482 included subjects, 7,463 had no his-
tory of liver disease (naive population) and 19 had a his-
Figure 1 Flow sheet of subjects included.
Table 2: Characteristics of 209 subjects with FibroTest >0.48 (presumed advanced fibrosis) in the population without a 
history of liver disease
Characteristics All Reinvestigated Not 
reinvestigated
Presumed fibrosis Fibrosis Confirmed Fibrosis still 
suspected
Indeterminate All reinvestigated
Number of subjects 209 50 27 28 105 104
Prevalence of fibrosis1 209/7,463 (2.8%) 100/7,463 (1.3%) 54/7,463 (0.7%) 56/7,463 (0.8%) 100/7,463 (1.4%) 104/7,463 (1.4%)
Cause of liver disease
Non alcoholic fatty liver 
disease2
98 (47%) 18 (35%) 10 (40%) 13 (46%) 41 (39%) 57 (55%)
Alcoholic liver disease3 15 (7%) 4 (8%) 1 (4%) 4 (14%) 9 (9%) 6 (6%)
Non alcoholic and 
alcoholic
61 (29%) 22 (42%) 11 (44%) 6 (21%) 39 (37%) 22 (21%)
Chronic hepatitis C 6 (3.5%) 4 (8%) 0 1 (4%) 5 (5%) 1 (1%)
Chronic hepatitis B 3 (1.4%) 1 (2%) 1 (4%) 0 3 (3%) 0 (0%)
Hemochromatosis 1 (0.5%) 1 (2%) 0 0 1 (1%) 0 (0%)
Auto-immune hepatitis 1 (0.5%) 0 (0%) 1 (4%) 0 1 (1%) 0 (0%)
No risk factor 25 (12%) 2 (4%) 1 (4%) 3 (11%) 7 (7%) 18 (17%)
Liver complications
H e p a t o c e l l u l a r  c a r c i n o m a N P 0  ( 0 % ) 000N P
Portal hypertension NP 1 (2%) 0 0 1 (1%) NP
Stage presumed fibrosis
Few septa 128 (61%) 26 (50%) 18 (72%) 22 (79%) 66 (63%) 62 (60%)
Many septa 56 (27%) 17 (33%) 6 (24%) 5 (18%) 28 (27%) 28 (27%)
Cirrhosis 25 (12%) 9 (17%) 1 (4%) 1 (3%) 11 (10%) 14 (13%)
Mode of confirmation4
Elastography NP 47 (90%) (>= 7.1 kPa) 27 (100%) (5kPa-
7kPa)
28 (100%) (<5kPa) 102(95%) NP
Biopsy NP 3 (5%) 0 1 (4%) 4 (4%) NP
Endoscopy NP 1 (2%) 0 0 1 (1%) NP
1 Estimated prevalence assuming that the prevalence of advanced ?brosis would be the same in the population of patients not reinvestigated. 2At least one factor of 
the metabolic syndrome without alcohol consumption at risk 3Alcohol consumption at risk self-reported or CDT >1.6% without metabolic factor 4Possibility of several 
confirmations for the same subject NP = not performedPoynard et al. BMC Gastroenterology 2010, 10:40
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Table 3: Predictive values of oriented screening strategies
Strategy Number subjects Presumed fibrosis Confirmed fibrosis
Prevalence fibrosis1 7463 209 (2.8%) 50 (0.7-1.4%)
Metabolic factors oriented
Predictive value
At least one metabolic factor 3990 163 (4.1%) 40 (1.0%)
None 3473 46 (1.3%) 10 (0.3%)
Odds ratio 7463 3.2 (2.3-4.5) 3.4 (1.7-7.5)
Area under ROC curve 4854 0.69(0.64-0.73) 0.71 (0.59-0.80)
Alcohol-oriented per self-
reported consumption
Predictive value
>10 g female/20 g male 1686 52 (3.1%) 15 (0.9%)
<= 10 g female/<= 20 g male 5770 157 (2.7%) 35 (0.6%)
Odds Ratio 7456 1.1 (0.8-1.6) 1.5 (0.8-2.8)
Area under ROC curve 7456 0.55(0.51-0.59) 0.52 (0.43-0.60)
CDT oriented
Predictive value
CDT>1.6 348 45 (12.9%) 22 (6.3%)
CDT<= 1.6 749 29 (3.9%) 8 (1.1%)
Odds Ratio 1097 3.7 (2.2-6.2) 6.1 (2.6-15.4)
Area under ROC curve 1097 0.72(0.64-0.78) 0.75 (0.67-0.86)
Hepatitis Virus-oriented2
Predictive value
HBsAg or HCV antibody 36 5 (13.9%) 3 (8.3%)
HBsAg and HCV negative or not done 
at baseline
7427 204 (2.7%) 47 (0.6%)
Odds ratio 7463 5.9 (1.9-15.6) 15.3 (3.4-50.9)
Transaminases- oriented
Predictive value
ALT >= 50 IU/L 513 53 (10.3%) 17 (3.3%)
ALT < 50 IU/L 6950 156 (2.2%) 33 (0.5%)
Odds ratio 7463 5.0 (3.6-7.0) 7.2 (3.8-13.4)
Area under ROC curve 7463 0.72(0.68-0.75) 0.78 (0.72-0.83)
Age-oriented
Predictive value
Age > 60 years 2960 156 (5.3%) 42 (1.4%)
Age <= 60 years 4503 53 (1.2%) 8 (0.2%)
Odds ratio 7463 4.7 (3.4-6.5) 8.3 (3.8-19.5)
Area under ROC curve 7463 0.75(0.72-0.78) 0.79 (0.71-0.84)
Gender-oriented
Male 4113 189 (4.6%) 47 (1.1%)
Female 3350 20 (0.6%) 3 (0.1%)
Odds ratio 7463 8.0 (5.0-13.1) 12.0 (4.0-54.1)
1 Upper estimated prevalence assuming that the prevalence of advanced fibrosis would be the same in the population of patients not reinvestigated. Lower 
prevalence assuming that no advanced fibrosis was present among patients not reinvestigated.
2 This strategy was the standard in the screening centers. Two cases with positive HBsAg detected during reinvestigations of advanced fibrosis were not taken into 
account. There was one coinfection HCV-HBV.Poynard et al. BMC Gastroenterology 2010, 10:40
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Table 5: Characteristics of naive subjects with and without discordance between FibroTest and LSM for the diagnosis of 
advanced fibrosis
Characteristics Discordance Significance
No Yes Univariate Multivariate
P OR 95%CI P
Number of subjects 698 68
Age at serum, years 57.0 59.7 0.04 1.02 1.00-1.06 0.048
Male (%) 349/698 (50%) 49/68 (72%) 0.0005 2.45 1.39-4.30 0.002
Thoracic fold 16.4 18.4 0.03 1.05 1.01-1.08 0.01
Operator effect 299/698 (43%) 40/68 (59%) 0.01 2.12 1.28-2.12 0.005
Cholesterol (mmol/L) 5.7 5.2 0.0002 0.58 0.44-0.76 <0.0001
Weight (kg) 69.4 73.2 0.04 Not Included final model NS
Waist circumference 83 87 0.005 Not Included final model NS
Body mass index 24.6 25.1 0.28 Not Included final model NS
ALT 24.7 28.2 0.007 Not Included final model NS
Fasting Glucose (mmol/L) 5.3 5.6 0.01 Not Included final model NS
HDL-cholesterol (mmol/L) 0.61 0.55 0.002 Not Included final model NS
Triglycerides (mmol/L) 1.2 1.2 0.81 Not Included final model NS
SteatoTest 0.31 0.36 0.04 Not Included final model NS
Table 4: Multivariate analysis of factor associated with advanced fibrosis
Factor Presumed fibrosis1 Confirmed fibrosis1
OR (95%CI)
All subjects n = 7395 R2 = 0.22 R2 = 0.20
Age 1.12 (1.10-1.14) <0.0001 1.13 (1.09-1.16) <0.0001
Male gender 4.31 (2.62-7.08) <0.0001 6.36 (2.03-22.1) 0.002
Waist 1.03 (1.01-1.04) 0.0002 1.05 (1.02-1.07) 0.001
Triglycerides1 1.32 (1.21-1.45) <0.0001 1.22 (1.07-1.39) 0.001
Total cholesterol 0.61 (0.52-0.72) 0.04 0.81 (0.60-1.11) 0.19
Fasting glucose 1.15 (1.05-1.26) 0.002 1.11 (0.94-1.32) 0.21
Reported alcohol 1.00 (0.99-1.01) 0.99 (0.97-1.01) 0.33
CDT assays1 n = 1076 R2 = 0.31 R2 = 0.31
CDT 2.09 (1.42-3.05) 0.0002 2.11 (1.39-3.20) 0.0005
CDT assays and HCV antibody1 testing n = 500 R2 = 0.35 R2 = 0.36
CDT 1.82 (1.21-2.73) 0.004 1.78 (1.24-2.56) 0.01
HCV positive 18.0 (2.43-132.7) 0.005 26.8 (2.75-261.3) 0.005
1 When CDT entered the models, the impact of serum triglycerides disappeared.Poynard et al. BMC Gastroenterology 2010, 10:40
http://www.biomedcentral.com/1471-230X/10/40
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tory (Figure 1). The characteristics of the included
population were similar to those of the French general
population (Additional file 1) [21,22]. A total of 3362/
7482 (45%) subjects received at least one treatment the
day of inclusion, but no specific details were available.
Prevalence of fibrosis
In the naïve population, 209/7463 (2.8%; 2.4%-3.2%) sub-
jects [N (%:95%CI)] had a FT with presumed fibrosis and
25 with presumed cirrhosis (0.3%; 0.2%-0.5%); 1336/7395
(18.1%; 17.2%-18.9%) had a SteatoTest with presumed ste-
atosis (over 5% of hepatocytes) and 80/7463 (1.1%; 0.8%-
1.3%) had a NashTest with presumed steato-hepatitis.
A total of 105 subjects accepted to be reinvestigated
(50% adherence) and were similar to the 104 subjects that
were not reinvestigated (Table 1). Fibrosis was confirmed
in 50, still suspected in 27, and indeterminate with a sus-
pected false positive of FT or false negative of LSM in 28
(T able 2). Only four subjects (4%) accepted liver biopsy
out of the 105 that were reinvestigated. Nine subjects had
confirmed cirrhosis, all without any clinically obvious
signs. One subject had small esophageal varices. Non-
alcoholic and alcoholic fatty liver diseases were the most
frequent etiologies (85%) for advanced fibrosis (Table 2).
Among patients with confirmed cirrhosis, 22% had HCV
(all associated with ALD), 44% had ALD and NAFLD and
33% had NAFLD alone (Additional File 2). Correlation
between first and second FT was 0.77 (P < 0.0001) with a
significant concordance between cirrhosis/non cirrhosis
(kappa = 0.76; P < 0.001).
The estimated prevalence of confirmed fibrosis was
1.3% (1.1%-1.7%) (Table 2). In a "worse" scenario assum-
ing that fibrosis was not present in patients not reinvesti-
gated, these overall estimated prevalences would have
been 0.7%.
Among the 19 subjects of the non-naïve population, 16
(84%) had an FT with presumed fibrosis; 13 subjects were
reinvestigated and the presumed fibrosis was confirmed
in 12 (positive predictive value 92%) using 10 LSM and
seven biopsies. If included, the prevalence of advanced
fibrosis ranged from 1.5% [(100+12)/(7463+19)] for con-
Table 6: Characteristics of discordant subjects at risk of false positive LSM or false negative FibroTest
Characteristics Discordant not reinvestigated Discordant reinvestigated
Number of subjects 30 18
Age >60 years 14/30 (47%) 4/18 (22%)
Male (%) 21 (70%) 12 (67%)
Fatty liver risk factor (Alcohol or 
metabolic)
Self-declared alcohol consumption at risk* 8/30 (27%) 2/18 (11%)
Elevated Carbohydrate Deficient 
Transferin (>1.6%)
9/30 (30%) 12/18 (67%) (P = 0.01)
Alcohol at risk (either consumption or CDT) 16/30 (53%) 13/18 (72%)
BMI >= 27.0 10/30 (33%) 4/18 (22%)
Metabolic factor of ATP-III classification 
(at least one)
Glucose >= 6.1 mmol/L or diabetes 
treatment
7/30 (23%) 2/18 (11%)
Central obesity waist >102 male >88 
female
7/30 (23%) 2/18 (11%)
Triglycerides >= 1.7 mmol/L or fibrate 
treatment
8/30 (27%) 2/17 (12%)
Hypertension or treatment 12/30 (40%) 2/18 (11%) (P = 0.05)
HDL-cholesterol <1.03 mmol/L male <1.29 
mmol/L female
2/30 (7%) 1/18 (6%)
Steatosis predicted by SteatoTest 7/30 (23%) 3/17 (18%)
HCV antibody positive 0/30 (0%) 0/18 (0%)
HIV antibody positive 0/30 (0%) 0/18 (0%)
HBsAg antigen positive 1/30 (3%) 0/18 (0%)
*More than one drink per day for female and more than two drinks per day for malePoynard et al. BMC Gastroenterology 2010, 10:40
http://www.biomedcentral.com/1471-230X/10/40
Page 9 of 13
firmed fibrosis to 3% [(209+16)/7463+19)] for presumed
fibrosis.
Factors associated with fibrosis
In univariate (Table 3) and multivariate analyses (Table
4), five factors were consistently and independently asso-
ciated with fibrosis (confirmed, or presumed): age, male
gender, waist circumference, alcohol consumption esti-
mated using CDT, and positive HCV antibodies.
Reported alcohol consumption was not associated with
advanced fibrosis. Serum triglycerides were no longer
associated with fibrosis when CDT was included in the
model (Table 4).
Comparison of screening strategies efficacy (Table 3)
The non selective strategy using FT in all subjects identi-
fied 0.7% (50/7,463) confirmed fibrosis cases, i.e., 149
subjects would be required to undergo fibrosis screening
in order to detect one case of advanced fibrosis.
The most sensitive selective screening strategy was the
metabolic factor-oriented strategy, which identified 40/50
(80%) confirmed advanced fibrosis cases, significantly
more than the alcohol-oriented strategy using self-
reported alcohol consumption and significantly more
than the standard HCV/HBV-oriented strategy.
Among 1097 subjects who had CDT measurements
(Additional File 3), the alcohol-oriented strategy using
CDT identified 22/30 (73%) confirmed fibrosis cases,
which did not differ from the metabolic strategy (23/30,
77%; P = 0.78 versus the CDT strategy), with both being
more sensitive than the alcohol-oriented strategy using
self-reported alcohol consumption.
Using the identified independent risk factors, the per-
centage of confirmed fibrosis detected among screened
subjects increased to 5.2% (30/581) for males, to 9.4%
(26/276) for males 60 years or older, to 16.4% (20/122) in
males 60 years or older with CDT over 1.6%, and to 28.6%
(6/21) in males 60 years or older with CDT over 1.6% and
waist circumference 102 cm or greater. The correspond-
ing number of subjects who would be required to
undergo fibrosis screening in order to detect one
advanced fibrosis was 19, 11, 6 and 4.
Subjects with possible underestimation of their alcohol
consumption (CDT greater than 1.6% and low self report
consumption represented 42% (30/72) of patients with
presumed advanced fibrosis versus 21% (216/1022; P =
0.0001) of patients without fibrosis. Using CDT versus
reported alcohol consumption, the attributable cause of
liver fibrosis was ALD in 16% (12/74) versus 5% (4/74),
mixed ALD/NAFLD in 45% (33/74) versus 23% (17/74),
and NAFLD in 34% (25/74) versus 55% (41/74), respec-
tively (P = 0.01).
Discordance analysis between FT and LSM
A total of 871 subjects had an interpretable FT and LSM,
766 during screening and 105 during reinvestigation.
During screening, the concordance between the 2 bio-
markers was 91.2% (P = 0.009) (Table 5) and 99.1% (761/
766 P < 0.0001) for the diagnosis of cirrhosis.
Using FT, 25 (3.3%) subjects had presumed advanced
fibrosis versus 53 (6.9%) subjects using LSM. 48 (6.3%)
subjects were suspected to be false negatives of FT or
false positives of LSM, and 20 (2.6%) false negatives of
LSM or false positives of FT. The 68 subjects with discor-
dance had significantly more factors already identified as
LSM variability factors than the other subjects. In multi-
variate analysis, male gender (OR = 2.45, 95%CI, 1.39-
4.30; P = 0.002), total cholesterol (negatively correlated
OR = 0.58, 95%CI, 0.44-0.76; P < 0.0001), thoracic fold
(OR = 1.05, 95%CI, 1.01-1.08; P = 0.01), and one operator
(OR = 2.12, 95%CI, 1.28-2.12; P = 0.005) were signifi-
cantly associated with discordance.
Estimate of FT false negative rate using LSM
Among the 48 (6.3%) subjects suspected to be false nega-
tives of FT or false positives of LSM, 18 accepted to be
reinvestigated (Table 6). Repeated FT results were consis-
tently lower than 0.48. Repeated LSM in twelve subjects
was no longer elevated and the false positivity of initial
LSM was highly suspected; in 11 of these 12 subjects the
initial LSM had been assessed by the "discordant" opera-
tor, and 4 had a thoracic fold over 15 mm. One case of a
false negative FT was highly suspected, as the second
LSM was still elevated (7.1 kPa) without any LSM vari-
ability risk factor. If the rate of false negative was the same
in reinvestigated or not reinvestigated subjects, a total of
3 false negative FTs would have been expected among the
48 discordant cases, i.e., an overall false negative rate of
0.4% (3/766).
Discussion
This study has limitations, but for the first time noninva-
sive biomarkers have been used to assess the prevalence
of advanced liver fibrosis, to identify the independent
associated risk factors and to prepare mass screening
strategies. This study is a first step in order to assess the
feasibility of using biomarkers, and not designed to assess
the treatment and follow-up of the screen-detected
patients [1]. The best method for validating a mass
screening strategy is probably a large randomized trial
[1]. The costs also were not estimated and compared. The
diagnostic performance of FT is superior to other non-
patented fibrosis biomarkers (i.e; APRI) but the cost is
greater [4-6]. If accepted in screening strategies, the pat-
ented tests' price should be reduced according to the
market volume and cost-benefit analyses.Poynard et al. BMC Gastroenterology 2010, 10:40
http://www.biomedcentral.com/1471-230X/10/40
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Benefit-risk of biomarkers
The present study is based on the assumption that FT and
LSM have been sufficiently validated to be used as first-
line screening and confirmation tests, respectively, for the
diagnosis of advanced fibrosis, without the use of liver
biopsy.
If these validations are accepted, biopsy is not neces-
sary. It is because biomarkers have been previously vali-
dated that large screening studies are possible without the
limitations of biopsy. To reduce the risk of false positive
and false negative we used two validated biomarkers, the
most sensitive being FT used as the screen test and elas-
tography as a confirmatory test.
Up until recently, only liver biopsy was considered as a
gold standard for the confirmation of suspected advanced
fibrosis in subjects with abnormal standard liver tests [4].
Previous studies performed in community-based popula-
tions mostly used transaminases ALT as a first-line
screening test [23-26]. This standard design is not accu-
rate due to limitations of both standard liver tests and
liver biopsy. Standard liver tests are significantly less
accurate than FT for the diagnosis and prognosis of
advanced fibrosis in patients with chronic hepatitis C, B,
ALD, and for the diagnosis of fibrosis in patients with
NAFLD [4-8]. In the present study only 33% of patients
with confirmed fibrosis had ALT greater or equal to 50
IU/L.
In the present study biopsy was proposed to all the
reinvestigated subjects with discordance between FT and
LSM. 98% out of discordant subjects refused the biopsy,
because of the risk of adverse events. In 2007 two deaths
a t t r i b u t a b l e  t o  l i v e r  b i o p s y  w e r e  r e p o r t e d  t o  a  F r e n c h
nationwide malpractice insurance company [27]. Besides
these risks liver biopsy is not a perfect reference standard
and even if all subjects with suspected fibrosis would have
accepted liver biopsy as a confirmation test, there still
would have been a risk of 25% for false positives/nega-
tives after liver biopsy [28,29]. Several diagnostic and pro-
spective prognostic studies have consistently
demonstrated that in case of discordances between FT
and biopsy, half of the cases were due to failure of biopsy
[5,6].
Other patented or not fibrosis biomarkers, ELF, Hepas-
core and Fibrometer, NAFLD fibrosis score are potential
candidates but have been less validated than FT for their
diagnostic and prognostic values [4].
FT has limitations with a risk of false positives due to
Gilbert's syndrome and hemolysis, as well a risk of false
negatives due to acute inflammation [6]. As previously
observed in blood donors and diabetics [12], the high-
risk profiles were rare (0.4%) in the present study with
99.6% applicability. Among applicable subjects the esti-
mated rate of false negatives was 0.4% and the false posi-
tive rate ranged according to fibrosis definition from
0.08% to 1.4%.
LSM has been validated as an alternative to liver biopsy
for the diagnosis of advanced fibrosis in the most fre-
quent liver diseases [9,30]. Compared to FT, the main dis-
advantages of LSM for a first-line test are the lower
applicability rate, the higher number of variability factors
including a possible operator effect and the lower sensi-
tivity for earlier stages of fibrosis [10].
In the present analysis we focus on confirmed fibrosis,
which is a minimal hypothesis in term of efficacy . The
fact that 50% of patients with presumed advanced fibrosis
have not been confirmed by LSM can be viewed as a
weakness of the present study. These individuals declined
a biopsy and they could be false positive of FT or false
negative of LSM. We acknowledge that the strategy com-
bining FT as a first-line screening test and LSM as a con-
firmation test magnified the complimentary advantages
of these two biomarkers for F3 and F4 but not for F2. We
previously observed a lower sensitivity of LSM versus FT,
for early stage F2 in patients with NAFLD, but this point
must be confirmed by other studies [11]. If the higher
accuracy of FT for the diagnosis of F2 is confirmed the
screening efficacy would be doubled.
Prevalence of advanced liver fibrosis
Depending on the definitions, and on bias related to the
non reinvestigated population, the estimated prevalence
of advanced fibrosis varied from 0.7% to 2.8%. However
the lower estimated prevalence of 0.7% seems not realis-
tic as the non reinvestigated population was similar to the
reinvestigated population for the main characteristics
(Table 1).
Using standard liver tests, a higher prevalence of
"chronic liver disease" was observed in Italy, the USA and
China, from 7.9% to 17.5% of estimates [23-26,31]. With-
out specific markers of advanced fibrosis, the attributable
cause of abnormal liver tests could include non severe
liver disease that is steatosis, or inflammation without
advanced fibrosis.
In the present study the most common attributable
cause of fibrosis was NAFLD associated with ALD or
alone (77%), much higher than hepatitis C (8%) and ALD
alone (8%). Among subjects with confirmed cirrhosis,
HCV infection was more prevalent (22%), and was always
associated with alcohol consumption. This study was not
designed to estimate the possible role of drugs in induc-
ing liver injury.
Other studies in the general population have also found
NAFLD to be the leading cause of suspected chronic liver
disease [23-26]. In the present study the prevalence of
steatosis assessed using SteatoTest was expected, 18% for
moderate to severe grade and 23% for minimal steatosis,
as well as 1% for NASH.Poynard et al. BMC Gastroenterology 2010, 10:40
http://www.biomedcentral.com/1471-230X/10/40
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One original observation of the present study was that
the use of CDT, a biomarker of excessive alcohol con-
sumption, instead of self-reported alcohol consumption,
permitted to attribute fibrosis to ALD 3 times more often
and to mixed ALD/NAFLD 2 times more often. One lim-
itation of the present study was that CDT was assessed in
a subpopulation of 1097 consecutive subjects and these
results need to be replicated in a larger population. The
cost of CDT is also a limitation for large screening strate-
gies.
Risk factors
The results confirmed that age, male gender and HBsAg
o r  H C V  a n t i b o d i e s  w e r e  a s s o c i a t e d  w i t h  f i b r o s i s .  T h e
original observation was that waist circumference was
the best independent predictive factor for fibrosis among
the "metabolic factors", when CDT was used as a bio-
marker of alcohol consumption. The significant associa-
tion between triglycerides and fibrosis was no longer
significant after adjustment using CDT. This was
expected, as triglycerides are associated both with meta-
bolic factors and alcohol consumption; finally, this obser-
vation also supports a lack of sensitivity of self-reported
alcohol consumption.
Screening strategies
The results suggest that the non selective strategy using
FT as a first-line test in the social security health centers
and elastography in the reference center seems feasible
and effective.
According to official recommendations, so far only
screening for alcohol misuse in adults, and lipid disorder
in men aged 35 and older are recommended in general
population. Screening for hepatitis B or C or hemochro-
matosis in general population are not recommended
[1,32]. For primary liver cancer two randomized trials
have suggested the efficacy of cancer screening in chronic
carriers of hepatitis B virus [33,34]. In the present study
the standard "hepatitis oriented strategy" was less effec-
tive than a non selective strategy.
Advantages and limitations of the non selective strategy
The advantage of the present screening was a simple defi-
nition of target population and individuals: subjects vol-
unteers affiliated to the national social security system
(covering 90% of French people), of 40 years or older con-
sulting in health centers. Another advantage is the accep-
tance rate of FT in this population (99.8%) and the high
rate of interpretable FT (99.6%).
A mean of 144 subjects would be required to undergo
fibrosis screening in order to detect one advanced fibrosis
case. This effectiveness is comparable to published strate-
gies screening for advanced colon neoplasia [35].
Only 50% of subjects with presumed advanced fibrosis
have been re-investigated (compliance with elastography
recommendation) in clinical facilities, despite two letters.
This rate is the usual magnitude of screening strategies
for colon cancer but lower than that observed for prostate
cancer screening (86% compliance with biopsy recom-
mendation) [36]. This point should be improved.
Effectiveness and limitations of selective strategies
The usual selective strategy used in the health centers,
oriented to hepatitis C and B high-risk subjects, was sig-
nificantly less effective due to a lack of sensitivity. This is
in accordance with other areas such as cancer screening
[1].
Using four simple identified independent factors (gen-
der, age, alcohol consumption estimated with CDT, and
waist circumference), the number of subjects required to
undergo fibrosis screening in order to detect one
advanced fibrosis case already decreased from 149 to 11
for men aged 60 years or older. This is comparable to the
number of men required to undergo colonoscopy screen-
ing in order to detect one advanced case of neoplasia,
which ranged from 23 to 10 according to age [35]. How-
ever this could be different for a strategy designed for cir-
rhosis screening as metabolic factors are less associated
so far with cirrhosis than chronic viral hepatitis.
Conclusions
Non invasive biomarker FibroTest has permitted to esti-
mate prevalence of advanced fibrosis around 2.8% in a
French general population aged 40 years or older. It has
also permitted to identify several independent risk fac-
tors which may be used for the validation of selective or
non-selective screening strategies.
These results suggest to organize a large randomized
trial in order to estimate the impact of fibrosis screening
on liver related complications and mortality.
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